Response letter on Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib—new ammunition in battling exon 17 mutations

Lignende værker

• Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib—new ammunition in battling exon 17 mutations
  af: Eckardt, Alexander J., et al.
  Udgivet: (2018)
• A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17
  af: Yeh, Chun-Nan, et al.
  Udgivet: (2017)
• Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
  af: Grellety, Thomas, et al.
  Udgivet: (2015)
• Targeting gastrointestinal stromal tumors: the role of regorafenib
  af: Schroeder, Brett, et al.
  Udgivet: (2016)
• Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?
  af: Şendur, Mehmet Ali Nahit, et al.
  Udgivet: (2013)